UNIVERSAL RAW MATERIAL PHARMA : revenue, balance sheet and financial ratios

UNIVERSAL RAW MATERIAL PHARMA is a French company founded 11 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in ORMESSON-SUR-MARNE (94490), this company of category PME shows in 2022 a revenue of 3.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - UNIVERSAL RAW MATERIAL PHARMA (SIREN 809460280)
Indicator 2024 2023 2022 2021 2019 2017
Revenue N/C N/C 3 876 563 € 1 805 972 € 3 006 650 € 2 282 690 €
Net income 726 704 € 641 985 € 545 195 € 240 151 € 420 454 € 377 816 €
EBITDA N/C N/C 704 438 € 323 020 € 582 362 € 566 955 €
Net margin N/C N/C 14.1% 13.3% 14.0% 16.6%

Revenue and income statement

In 2024, UNIVERSAL RAW MATERIAL PHARMA generates positive net income of 727 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 378 k€ -> 727 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

726 704 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 2%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 78%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

1.658%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

78.288%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

19.5%

Solvency indicators evolution
UNIVERSAL RAW MATERIAL PHARMA

Sector positioning

Debt ratio
1.66 2024
2022
2023
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Good -12 pts over 3 years

In 2024, the debt ratio of UNIVERSAL RAW MATERIAL PH... (1.66) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
78.29% 2024
2022
2023
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Excellent +10 pts over 3 years

In 2024, the financial autonomy of UNIVERSAL RAW MATERIAL PH... (78.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.13 years 2022
2022
Q1: 0.0 years
Med: 0.01 years
Q3: 1.6 years
Average

In 2022, the repayment capacity of UNIVERSAL RAW MATERIAL PH... (0.13) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 489.79. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

489.788

Liquidity indicators evolution
UNIVERSAL RAW MATERIAL PHARMA

Sector positioning

Liquidity ratio
489.79 2024
2022
2023
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Excellent +7 pts over 3 years

In 2024, the liquidity ratio of UNIVERSAL RAW MATERIAL PH... (489.79) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
0.11x 2022
2022
Q1: 0.0x
Med: 0.34x
Q3: 4.26x
Average

In 2022, the interest coverage of UNIVERSAL RAW MATERIAL PH... (0.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
UNIVERSAL RAW MATERIAL PHARMA

Positioning of UNIVERSAL RAW MATERIAL PHARMA in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of UNIVERSAL RAW MATERIAL PHARMA is estimated at 596 998 € (range 227 222€ - 2 180 163€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
227k€ 596k€ 2180k€
596 998 € Range: 227 222€ - 2 180 163€
NAF 5 all-time

Valuation method used

Net Income Multiple
726 704 € × 0.8x = 596 999 €
Range: 227 222€ - 2 180 164€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare UNIVERSAL RAW MATERIAL PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about UNIVERSAL RAW MATERIAL PHARMA

What is the revenue of UNIVERSAL RAW MATERIAL PHARMA ?

The revenue of UNIVERSAL RAW MATERIAL PHARMA in 2022 is 3.9 M€.

Is UNIVERSAL RAW MATERIAL PHARMA profitable?

Yes, UNIVERSAL RAW MATERIAL PHARMA generated a net profit of 727 k€ in 2024.

Where is the headquarters of UNIVERSAL RAW MATERIAL PHARMA ?

The headquarters of UNIVERSAL RAW MATERIAL PHARMA is located in ORMESSON-SUR-MARNE (94490), in the department Val-de-Marne.

Where to find the tax return of UNIVERSAL RAW MATERIAL PHARMA ?

The tax return of UNIVERSAL RAW MATERIAL PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does UNIVERSAL RAW MATERIAL PHARMA operate?

UNIVERSAL RAW MATERIAL PHARMA operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.